Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.

The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss ...

Eli Lilly stock has been climbing back from a recent pullback and nearing a buy point. The drugmaker teamed up with Nvidia on ...

GLP-1 giant Eli Lilly has once again taken to the medium of short film to deliver an important message about obesity. | GLP-1 ...

Novo Nordisk stock moved higher after oral Wegovy logged over 18,000 first-week prescriptions, with Goldman Sachs boosting sentiment via a Buy rating.

Novo Nordisk's Wegovy pill was prescribed 18,410 times in the U.S. in the first full week after its launch in an encouraging ...

Novo Nordisk's Wegovy ​pill was prescribed more than 18,000 times in the U.S. in the first full week after ‌its launch in an ...

The early response illustrates how quickly patients and doctors are using the oral form of the company's best-selling obesity medicine, which was only accessible as an injectable until now. IQVIA data ...

With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the ...

Novo Nordisk's Wegovy pill tracked 18,410 U.S. prescriptions in the first full week after its launch, IQVIA data shared by ...

Eli Lilly ( LLY +0.87%) delivered a gain worthy of a technology growth stock last year. The pharma giant's shares soared 39%, ...

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco.